Key Takeaways Current GLP-1 weight-loss meds need to be taken as injections, but new trial results suggest a GLP-1 in pill ...

Orforglipron, a GLP-1 drug taken as a pill, achieved positive results in people with obesity and type 2 diabetes, although it ...

An oral weight loss pill has performed well in clinical trials, positioning it as a potential alternative to injectable GLP-1 medications like Ozempic and Wegovy. The Eli Lilly drug, called ...

Eli Lilly and Co.’s experimental obesity pill helped patients lose 9.6% of their body weight in a trial that moves the company one step closer to a potential approval. The company’s shares rose as ...

Share on Pinterest GLP-1 drugmaker Eli Lilly’s new weight loss pill orforglipron showed meaningful weight loss results in a recent clinical trial. Scott Olson/Getty Images Eli Lilly’s new oral GLP-1 ...

In an Aug. 7 earnings call, Eli Lilly CEO David Ricks told investors that the company plans to submit the drug, orforglipron, to the FDA for approval by the end of the year. Dan Skovronsky, chief ...

Shares of Viking Therapeutics plummeted more than 43% Tuesday after the company revealed poorer-than-expected mid-stage trial data for its experimental weight-loss pill, joining Eli Lilly with similar ...

An intriguing new option is coming for weight-loss drugs: a pill that you take once a day to shed pounds, rather than the weekly injections that have powered the anti-obesity revolution up to now. The ...

Eli Lilly, the maker of Zepbound and Mounjaro, said its experimental GLP-1 pill successfully helped adults with obesity lose weight in a Phase 3 trial, as the company moves closer to submitting the ...